Stock listing

LS Exchange:A2P208 ORIC Pharmaceuticals, Inc. Aktie

German listing (LS Exchange) of ORIC Pharmaceuticals, Inc. · home listing NASDAQ:ORIC

Follow ORIC Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:ORIC

$7.36 USD -0.29 (-3.8%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:ORIC

Past year -35.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$7.28 – $8.00 USDNov 20, 2026
Volume
1.46M sharesNov 20, 2026
Market cap
$764.9M USDAt the close on Nov 20, 2026 · price × 103.9M shares outstanding
52-week range
$7.23 – $14.68 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$17.91M USDMedian day 1.23M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
ORIC Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ORIC · Home$7.36 USD-0.29 (-3.8%)1,455,496$7.58$8.00$7.275$7.65Close on Nov 20, 2026
Frankfurt:4TZ€6.958 EUR+0.092 (+1.3%)—€6.874€6.958€6.874€6.866Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ORIC · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$7.36-0.29-3.8%$7.58$8.00$7.2751,455,496
$7.65-0.35-4.4%$7.91$8.04$7.531,385,239
$8.00+0.48+6.4%$7.71$8.01$7.582,000,019
$7.52-0.34-4.3%$7.76$7.99$7.501,196,164
$7.86-0.64-7.5%$8.50$8.67$7.831,008,732
$8.50-0.50-5.6%$8.77$8.86$8.451,178,749
$9.00+0.09+1.0%$8.95$9.15$8.84773,284
$8.91-0.32-3.5%$9.11$9.453$8.761,011,307
$9.23+0.41+4.6%$8.89$9.37$8.741,228,508
$8.82+0.33+3.9%$8.61$8.93$8.50556,747
$8.49-0.85-9.1%$9.32$9.34$8.461,390,438
$9.34-0.25-2.6%$9.98$10.13$9.0652,958,658
$9.59+0.52+5.7%$9.17$10.00$9.173,555,380
$9.07-0.17-1.8%$9.285$9.38$9.001,922,647
$9.24+0.25+2.8%$8.87$9.80$8.2752,441,596
$8.99-0.31-3.3%$9.31$9.70$8.961,046,758
$9.30+0.30+3.3%$8.80$9.33$8.601,413,970
$9.00+0.045+0.5%$8.96$9.24$8.654,938,899
$8.955-4.215-32.0%$13.10$13.24$8.886,952,473
$13.17-0.46-3.4%$13.10$13.49$12.731,388,800
$13.63-0.22-1.6%$13.67$14.14$13.381,150,761
$13.85+0.07+0.5%$13.81$14.20$13.741,568,849
$13.78+1.06+8.3%$12.79$14.31$12.522,019,250
$12.72+0.37+3.0%$12.46$12.74$12.141,187,758
$12.35-0.42-3.3%$12.75$12.75$12.03946,200
$12.77+1.18+10.2%$11.74$12.89$11.531,557,455
$11.59+0.28+2.5%$11.35$11.84$11.201,791,371
$11.31-0.50-4.2%$11.68$11.92$11.291,158,249
$11.81-0.18-1.5%$12.06$12.26$11.73878,260
$11.99-0.04-0.3%$11.98$12.29$11.901,086,585
$12.03+0.02+0.2%$11.87$12.20$10.932,695,530
$12.01+0.03+0.3%$11.83$12.43$11.81790,782
$11.98-0.51-4.1%$12.60$12.60$11.562,091,856
$12.49+0.285+2.3%$12.65$12.65$11.891,395,684
$12.21-0.315-2.5%$12.72$12.93$12.171,232,084
$12.52-0.95-7.1%$13.42$13.62$12.511,770,890
$13.47+0.10+0.7%$13.51$14.12$13.331,961,192
$13.37+0.10+0.8%$13.23$13.42$12.76977,262
$13.27+0.11+0.8%$13.14$13.72$12.761,515,563
$13.16-0.02-0.2%$13.27$13.49$12.942,493,810
$13.18-0.15-1.1%$13.22$13.51$12.791,995,576
$13.33-0.17-1.3%$13.94$14.00$12.941,717,561
$13.50+0.83+6.6%$12.73$13.53$12.541,157,584
$12.67-0.12-0.9%$12.98$13.01$12.50835,961
$12.79-0.09-0.7%$12.81$12.91$12.483,090,944
$12.88+0.34+2.7%$12.87$13.22$12.661,156,336
$12.54+0.18+1.5%$12.38$12.84$12.171,609,372
$12.36-0.29-2.3%$12.60$12.65$11.952,052,561
$12.65+0.61+5.1%$12.02$12.69$11.861,618,209
$12.04-0.03-0.2%$12.26$12.41$12.001,063,007
$12.07-0.43-3.4%$12.64$12.79$12.011,027,306
$12.50-0.12-1.0%$12.50$13.00$12.311,669,253
$12.62-0.24-1.9%$12.67$12.87$12.54955,399
$12.86+0.12+0.9%$12.51$12.99$12.51991,453
$12.74-0.39-3.0%$13.17$13.41$12.59916,441
$13.13+0.24+1.9%$12.97$13.53$12.831,546,226
$12.89-0.10-0.8%$12.82$13.06$12.77646,365
$12.99-0.25-1.9%$13.18$13.18$12.671,158,805
$13.24-0.50-3.6%$13.59$13.93$13.20765,429
$13.74-0.17-1.2%$13.96$14.25$13.651,060,961
$13.91+0.08+0.6%$13.74$13.97$13.481,123,808
$13.83+0.37+2.7%$13.71$14.15$13.521,168,791
$13.46-0.74-5.2%$14.16$14.52$13.441,110,088
$14.20+0.32+2.3%$14.00$14.34$13.81970,493
$13.88-0.77-5.3%$14.32$14.52$13.771,176,680
Ticker
LS Exchange:A2P208
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LS Exchange
Currency
EUR

What changed lately

Latest news

All ORIC Pharmaceuticals, Inc. news

ORIC Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
28 in the last 12 months · 137 in all · newest Nov 16, 2026 · oldest 2020
Calls
1 call with a replay · 1 with a transcript · latest Mar 21, 2022
Decks
12 decks · latest Oct 23, 2026

Where ORIC Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ORIC · Home listingNASDAQUnited StatesUSD
LS Exchange:A2P208 · This pageLS ExchangeGermanyEUR
Lang & Schwarz:A2P208Lang & SchwarzGermanyEUR
gettex:4TZgettexGermanyEUR
BOATS:ORICBOATSUnited StatesUSD
Tradegate:4TZTradegateGermanyEUR
Dusseldorf:4TZDusseldorfGermanyEUR
Frankfurt:4TZFrankfurtGermanyEUR
Hamburg:4TZHamburgGermanyEUR
Munich:4TZMunichGermanyEUR
Stuttgart:4TZStuttgartGermanyEUR

Valuation

Price/book 2.3× against a median of 3.4×: 3rd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$503.6M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.22

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
ORIC Pharmaceuticals, Inc. · NASDAQ:ORICUS$764.9MUS$503.6Mn/an/an/a2.3×n/a0.0×1.22
Arbutus Biopharma Corporation · NASDAQ:ABUSUS$796.4MUS$458.9M3.6×2.5×3.1×9.3×121.2%0.0×1.10
Genfleet Therapeutics (Shanghai), Inc. Class H · HKEX:2595US$787.5MUS$518.8Mn/a26.5×n/a3.3×n/a0.0×n/a
Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H · HKEX:2335US$778.7MUS$599.6Mn/an/an/a5.5×n/a0.0×n/a
Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWDUS$778.1MUS$702.9M5.2×1.8×n/an/a37.4%n/a1.16
Syndax Pharmaceuticals, Inc. · NASDAQ:SNDXUS$772.7MUS$695.6Mn/a2.4×n/an/a−72.4%n/a0.64
MeiraGTx Holdings plc · NASDAQ:MGTXUS$766.4MUS$715.6M9.8×1.8×3.7×3.6×19.5%0.6×1.57
Inventiva SA · EURONEXT:IVAUS$760.9MUS$577.3Mn/a117×n/a11.8×n/a1.1×n/a
Rigel Pharmaceuticals, Inc. · NASDAQ:RIGLUS$754.9MUS$663.4M2.5×2.3×8.3×1.7×106.6%0.0×1.02
Obsidian Therapeutics, Inc. · NASDAQ:OBXUS$741.3MUS$530.4M13.0×n/an/a2.3×n/a0.0×n/a
Monte Rosa Therapeutics, Inc. · NASDAQ:GLUEUS$738.3MUS$196.8Mn/a2.8×n/a1.5×−186.2%0.1×0.92
Median of the othersUS$769.6MUS$588.5M5.2×2.5×3.7×3.4×28.4%0.0×1.06

Forecasts

12 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.

Price target
21.79 USD · Analysts' mean
EPS, year to Dec 2026
-1.59 · 8 analysts

Team and board

Officers

OfficerRole
Angie YouBoard Member, CEO of Architect Therapeutics
Jacob ChackoPresident, Chief Executive Officer
Steve L. HoerterBoard Member, Chairman and CEO of MBX Biosciences
Dominic PiscitelliChief Financial Officer
Christian V. KuhlenGeneral Counsel and Chief Compliance Officer
Dan IazzettiVice President, Head of People
Edna Chow ManevalExecutive Vice President, Clinical Development
Keith LuiSenior Vice President, Commercial and Medical Affairs
Kevin Brodbecknewly established role of Chief Technical Officer
Lori FriedmanChief Scientific Officer
Matthew PanuwatChief Business Officer
Pratik MultaniChief Medical Officer

Board

DirectorRole
Richard HeymanChairman
Steve L. HoerterBoard Member, Chairman and CEO of MBX Biosciences
Angie YouBoard Member, CEO of Architect Therapeutics
Jacob ChackoPresident, Chief Executive Officer
Lori KunkelBoard Member
Mardi C. DierBoard Member

Events

Calls

CallWhenStatus
ORIC Pharmaceuticals (NASDAQ:ORIC) Q4 2021 Earnings CallMon, Mar 21, 2022 · 5:00 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 16, 2026 · After close+6.4%
Q2 2026Aug 3, 2026 · After close+27.1%
Q1 2026May 4, 2026 · After close−0.6%
Q4 2025Mar 24, 2026+5.1%
Q3 2025Nov 13, 2025 · After close+0.5%
Q2 2025Aug 12, 2025 · After close+3.3%
Q1 2025May 5, 2025 · After close−11.6%
Q4 2024Mar 10, 2025 · Before open−4.6%
Q3 2024Nov 12, 2024 · After close+0.1%
Q2 2024Aug 12, 2024 · After close+6.8%
All 20 quarters
QuarterResultsShare move
Q1 2024May 6, 2024 · After close+2.6%
Q4 2023Mar 11, 2024 · After close−4.5%
Q3 2023Nov 6, 2023 · After close−0.7%
Q2 2023Aug 10, 2023 · After close+11.0%
Q1 2023May 8, 2023 · After close−2.5%
Q4 2022Mar 16, 2023 · After close−8.6%
Q3 2022Nov 7, 2022 · After close+3.7%
Q2 2022Aug 11, 2022 · After close+4.5%
Q1 2022May 9, 2022 · After close+5.2%
Q4 2021Mar 21, 2022 · After close−28.7%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (October 2026)Corporate update40 slidesOct 23, 2026
Investor Presentation (September 2026)Investor deck49 slidesSeptember 2026
Corporate Update (March 2026)Corporate update44 slidesMar 31, 2026
Technical Presentation (December 2025)Technical43 slidesDec 8, 2025
ESMO Asia 2025Conference19 slidesDec 6, 2025
Technical Presentation (December 2025)Technical19 slidesDec 6, 2025
ESMO 2025 Mini Oral PresentationConference10 slidesDec 5, 2025
Technical Presentation (November 2025)Technical9 slidesNov 13, 2025
Investor Presentation (January 2025)Investor deck43 slidesJan 13, 2025
Investor Presentation (January 2024)Investor deck43 slidesJan 9, 2024
All 12 decks
DeckKindSlidesDate
FY2021 Earnings PresentationEarnings15 slidesMar 21, 2022
Investor Presentation (January 2021)Investor deck41 slidesJan 11, 2021

Open Decks

Financings

RaiseDate
At-the-market programme of common stock
Closed: US$20M raised
Feb 23, 2026
At-the-market programme of common stock
Closed: US$119M raised
Aug 12, 2025
Private placement of common stock (or pre-funded warrants in lieu thereof)
Announced: about US$125M · US$6.5 a share
Buyers: SR One (leads the financing); Point72; Viking Global Investors; Venrock Healthcare Capital Partners; NEA; Nextech; Vivo Capital; NEXTBio Capital
Use of proceeds: Research and development of clinical-stage product candidates and research programs, working capital and general corporate purposes
May 28, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Apr 23, 2020.

Price
US$16.00 a share
Shares offered
7,500,000 shares of common stock
Offering size
US$120 million
Underwriters' option
Up to 1,125,000 more shares
Underwriters
J.P. Morgan, Citigroup, Jefferies, Guggenheim Securities · In the order on the cover
Shares delivered
On or about Apr 28, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceDec 13, 2019
Filed publiclyFeb 28, 2020
Amended twiceNewest Apr 23, 2020
Shares registered with an exchangeApr 20, 2020
Declared effective by the SECApr 23, 2020
Final prospectus, with the priceApr 24, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Apr 24, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue00000000
Cost of revenue1.22M1.11M1.03M966.0K897.0K970.0K1.00M900.0K900.0K
Gross profit-1.22M-1.11M-1.03M-966.0K-897.0K-970.0K-1.00M-900.0K-900.0K
Research and development109.8M114.1M85.2M61.7M56.9M35.9M22.8M19.0M19.1M
Selling, general and administrative33.2M28.8M25.6M25.1M22.0M13.4M5.72M3.35M3.42M
Operating income-143.0M-142.9M-110.8M-91.8M-78.9M-74.2M-28.6M-22.4M-22.5M
Depreciation and amortization1.22M1.11M1.03M966.0K897.0K970.0K1.03M903.0K900.0K
EBITDA-141.8M-141.8M-109.7M-90.8M-78.0M-73.2M-27.5M-21.5M-21.6M
Interest expense2.65M141.0K306.0K1.69M1.01M0
Income before tax-129.5M-127.8M-100.7M-89.1M-78.7M-73.7M-26.9M-21.4M-22.0M
Income tax00000000
Net income-129.5M-127.8M-100.7M-89.1M-78.7M-73.7M-26.9M-21.4M-22.0M
Earnings per share, basic-1.47-1.83-1.96-2.25-2.07-3.36-14.15-12.32-15.62
Earnings per share, diluted-1.47-1.83-1.96-2.25-2.07-3.36-14.15-12.32

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents45.7M59.4M23.4M66.8M226.0M78.4M89.2M42.6M25.8M
Short-term investments235.8M196.6M184.8M139.4M11.0M215.2M
Current assets288.5M262.3M212.6M210.5M240.5M296.7M90.0M43.7M26.6M
Property, plant and equipment2.42M2.92M2.86M3.25M2.41M1.98M2.24M2.51M2.90M
Total assets408.9M274.1M252.0M247.2M298.6M299.0M94.1M46.7M30.0M
Accounts payable3.82M1.55M944.0K1.32M1.89M757.0K152.0K446.0K940.0K
Current liabilities20.4M24.8M20.5M15.4M15.2M9.00M5.35M2.60M2.61M
Total debt3.33M3.18M10.2M12.1M10.5M
Total liabilities24.5M31.0M27.9M24.8M25.7M9.22M6.12M111.2M4.30M
Shareholders' equity384.4M243.1M224.1M222.4M273.0M289.8M-90.1M-64.4M25.7M
Shares outstanding98.5M71.0M54.9M45.1M39.4M36.7M1.98M39.4M1.41M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-111.0M-112.7M-85.7M-75.1M-59.5M-45.3M-23.5M-20.7M-20.8M
Capital spending-712.0K-1.19M-849.0K-2.08M-939.0K-667.0K-768.0K-525.0K-486.0K
Free cash flow-111.7M-113.8M-86.5M-77.2M-60.5M-45.9M-24.3M-21.2M-21.3M
Cash from investing-148.0M22.1M-43.4M-109.2M158.4M-216.0M-768.0K-508.0K-292.0K
Cash from financing245.3M126.5M85.7M25.2M49.1M250.5M70.8M38.0M260.0K
Share buybacks545.0K51.0M271.8M70.9M38.0M
Change in cash-13.7M36.0M-43.4M-159.2M148.0M-10.7M46.5M16.8M-20.9M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportNov 16, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
8-K · Current reportOct 23, 2026Current reportSEC
4 · Change in ownershipOct 21, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
144 · Notice of proposed saleOct 1, 2026Other filingsSEC
144 · Notice of proposed saleOct 1, 2026Other filingsSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipSep 29, 2026Insider tradeSEC
4 · Change in ownershipSep 25, 2026Insider tradeSEC
4 · Change in ownershipAug 28, 2026Insider tradeSEC
144 · Notice of proposed saleAug 26, 2026Other filingsSEC
10-Q · Quarterly reportAug 3, 2026Quarterly reportSEC
8-K · Current reportAug 3, 2026ResultsSEC
S-8 · Registration statement for employee plansJul 30, 2026Offer documentSEC
8-K · Current reportJul 30, 2026Management or board changeSEC
4 · Change in ownershipJul 28, 2026Insider tradeSEC
4 · Change in ownershipJul 8, 2026Insider tradeSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
8-K · Current reportJun 22, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 4, 2026Quarterly reportSEC
8-K · Current reportMay 4, 2026ResultsSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
8-K · Current reportMar 31, 2026Current reportSEC
4 · Change in ownershipFeb 26, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 24, 2026Other filingsSEC
8-K · Current reportFeb 23, 2026Current reportSEC
424B5 · ProspectusFeb 23, 2026Offer documentSEC
S-8 · Registration statement for employee plansFeb 23, 2026Offer documentSEC
10-K · Annual reportFeb 23, 2026Annual reportSEC
8-K · Current reportFeb 23, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 21, 2026Big-stake noticeSEC
4 · Change in ownershipJan 20, 2026Insider tradeSEC
144 · Notice of proposed saleJan 16, 2026Other filingsSEC
144 · Notice of proposed saleJan 16, 2026Other filingsSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2025Insider tradeSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
144 · Notice of proposed saleDec 16, 2025Other filingsSEC
4 · Change in ownershipDec 9, 2025Insider tradeSEC
8-K · Current reportDec 8, 2025Current reportSEC
4 · Change in ownershipDec 5, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 17, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
8-K · Current reportNov 13, 2025Current reportSEC
10-Q · Quarterly reportNov 13, 2025Quarterly reportSEC
8-K · Current reportNov 13, 2025ResultsSEC
4 · Change in ownershipOct 8, 2025Insider tradeSEC
4 · Change in ownershipOct 8, 2025Insider tradeSEC
144 · Notice of proposed saleOct 6, 2025Other filingsSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
4 · Change in ownershipSep 24, 2025Insider tradeSEC
144 · Notice of proposed saleSep 22, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
SCHEDULE 13G · Big-stake noticeAug 5, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 17, 2025Big-stake noticeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
424B3 · ProspectusJun 24, 2025Offer documentSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveJun 23, 2025Other filingsSEC
CORRESP · Letter to the SECJun 17, 2025Other filingsSEC
UPLOAD · Letter from the SECJun 16, 2025Other filingsSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
8-K · Current reportJun 13, 2025Meeting outcomeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
S-3 · Registration statementJun 11, 2025Offer documentSEC
4 · Change in ownershipJun 9, 2025Insider tradeSEC
144 · Notice of proposed saleJun 6, 2025Other filingsSEC
DJun 6, 2025Other filingsSEC
SCHEDULE 13D · Big-stake noticeJun 5, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJun 4, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeMay 30, 2025Big-stake noticeSEC
8-K · Current reportMay 28, 2025Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 5, 2025Quarterly reportSEC
8-K · Current reportMay 5, 2025ResultsSEC
ARS · Annual report to shareholdersApr 23, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2025Meeting noticeSEC
S-8 · Registration statement for employee plansMar 20, 2025Offer documentSEC
8-K · Current reportMar 14, 2025Management or board changeSEC
4 · Change in ownershipMar 4, 2025Insider tradeSEC
8-K · Current reportFeb 25, 2025Current reportSEC
10-K · Annual reportFeb 18, 2025Annual reportSEC
8-K · Current reportFeb 18, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
8-K · Current reportJan 13, 2025Current reportSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipDec 17, 2024Insider tradeSEC
4 · Change in ownershipDec 17, 2024Insider tradeSEC
4 · Change in ownershipDec 17, 2024Insider tradeSEC
144 · Notice of proposed saleDec 16, 2024Other filingsSEC
144 · Notice of proposed saleDec 16, 2024Other filingsSEC
144 · Notice of proposed saleDec 16, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 22, 2024Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
8-K · Current reportAug 12, 2024ResultsSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
4 · Change in ownershipJun 14, 2024Insider tradeSEC
8-K · Current reportJun 14, 2024Meeting outcomeSEC
4 · Change in ownershipJun 4, 2024Insider tradeSEC
10-Q · Quarterly reportMay 6, 2024Quarterly reportSEC
8-K · Current reportMay 6, 2024ResultsSEC
ARS · Annual report to shareholdersApr 24, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2024Meeting noticeSEC
S-8 · Registration statement for employee plansMar 29, 2024Offer documentSEC
8-K · Current reportMar 29, 2024Management or board changeSEC
S-3ASR · Registration statementMar 11, 2024Offer documentSEC
10-K · Annual reportMar 11, 2024Annual reportSEC
8-K · Current reportMar 11, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedMar 11, 2024Big-stake noticeSEC
4 · Change in ownershipMar 8, 2024Insider tradeSEC
144 · Notice of proposed saleMar 6, 2024Other filingsSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 8, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 7, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 6, 2024Big-stake noticeSEC
144 · Notice of proposed saleFeb 6, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveFeb 5, 2024Other filingsSEC
SC 13G · Big-stake noticeFeb 1, 2024Big-stake noticeSEC
CORRESP · Letter to the SECJan 31, 2024Other filingsSEC
UPLOAD · Letter from the SECJan 31, 2024Other filingsSEC
SC 13G · Big-stake noticeJan 30, 2024Big-stake noticeSEC
DJan 30, 2024Other filingsSEC
SC 13G · Big-stake noticeJan 29, 2024Big-stake noticeSEC
S-3 · Registration statementJan 26, 2024Offer documentSEC
SC 13G · Big-stake noticeJan 25, 2024Big-stake noticeSEC
8-K · Current reportJan 22, 2024Material contractSEC
8-K · Current reportJan 9, 2024ResultsSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
4 · Change in ownershipJan 3, 2024Insider tradeSEC
EFFECT · Notice that a registration is effectiveDec 29, 2023Other filingsSEC
CORRESP · Letter to the SECDec 26, 2023Other filingsSEC
UPLOAD · Letter from the SECDec 22, 2023Other filingsSEC
4 · Change in ownershipDec 19, 2023Insider tradeSEC
4 · Change in ownershipDec 19, 2023Insider tradeSEC
4 · Change in ownershipDec 19, 2023Insider tradeSEC
S-3 · Registration statementDec 15, 2023Offer documentSEC
8-K · Current reportDec 11, 2023Current reportSEC
10-Q · Quarterly reportNov 6, 2023Quarterly reportSEC
8-K · Current reportNov 6, 2023ResultsSEC
8-K · Current reportOct 23, 2023Current reportSEC
10-Q · Quarterly reportAug 10, 2023Quarterly reportSEC
8-K · Current reportAug 10, 2023ResultsSEC
4 · Change in ownershipJul 11, 2023Insider tradeSEC
4 · Change in ownershipJul 7, 2023Insider tradeSEC
SC 13G · Big-stake noticeJul 7, 2023Big-stake noticeSEC
144 · Notice of proposed saleJul 5, 2023Other filingsSEC

This page holds 200 of 428 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from ORIC Pharmaceuticals, Inc.’s releases · as of Nov 9, 2026

Common shares
103,931,597
Fully diluted
103,948,797

Fully diluted

LineSharesAs of
Common shares103,931,597Nov 9, 2026
Options and RSUs17,200Nov 2, 2026

Warrants and options

Lot
Stock options · expiry not stated
RSUs · expiry not stated

Share count over time

CountShares
Nov 9, 2026103,931,597

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Nextech Invest Ltd.7.16MUS$96.5MSep 30, 2026
BlackRock6.98MUS$94MSep 30, 2026
Vanguard5.41MUS$72.8MSep 30, 2026
T. Rowe Price5.09MUS$68.5MSep 30, 2026
AIHC Capital Management Ltd4.63MUS$62.4MSep 30, 2026
Sr One Capital Management, LP4.62MUS$62.2MSep 30, 2026
State Street4.13MUS$55.6MSep 30, 2026
NEA Management Company, LLC4.12MUS$55.5MSep 30, 2026
Viking Global Investors LP3.56MUS$48MSep 30, 2026
Column Group LLC3.54MUS$47.7MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Siren, L.L.C.3.36MUS$45.2MSep 30, 2026
Alkeon Capital Management LLC3.24MUS$43.6MSep 30, 2026
EcoR1 Capital, LLC3.03MUS$40.8MSep 30, 2026
Venrock Adviser, LLC2.94MUS$39.7MSep 30, 2026
Fidelity2.63MUS$35.5MSep 30, 2026
D. E. Shaw & Co., Inc.2.45MUS$33.1MSep 30, 2026
Defilade Capital Management, L.P.2.27MUS$30.6MSep 30, 2026
Geode Capital2.19MUS$29.6MSep 30, 2026
Citadel2.11MUS$28.4MSep 30, 2026
Morgan Stanley2.04MUS$27.4MSep 30, 2026
Dimensional1.9MUS$25.6MSep 30, 2026
Franklin Templeton1.89MUS$17.6MSep 30, 2026
Mpm Bioimpact LLC1.82MUS$24.5MSep 30, 2026
Goldman Sachs1.8MUS$24.3MSep 30, 2026
Integral Health Asset Management, LLC1.7MUS$20.2MSep 30, 2026
Qube Research & Technologies Ltd1.64MUS$22.1MSep 30, 2026
Algert Global LLC1.62MUS$21.8MSep 30, 2026
First Turn Management, LLC1.57MUS$21.2MSep 30, 2026
Orbimed Advisors LLC1.56MUS$21MSep 30, 2026
Paradigm Biocapital Advisors LP1.51MUS$20.3MSep 30, 2026
Woodline Partners LP1.43MUS$19.3MSep 30, 2026
Adage Capital Partners Gp, L.L.C.1.29MUS$17.3MSep 30, 2026
Casdin Capital, LLC1.25MUS$16.8MSep 30, 2026
Bank of America1.04MUS$14MSep 30, 2026
Squadron Capital Management LLC1MUS$13.5MSep 30, 2026
Braidwell LP991KUS$13.3MSep 30, 2026
Euclidean Capital LLC989KUS$13.3MSep 30, 2026
Vivo Capital, LLC924KUS$12.5MSep 30, 2026
Northern Trust803KUS$10.8MSep 30, 2026
Candriam S.C.A.788KUS$10.7MSep 30, 2026
Schwab771KUS$10.4MSep 30, 2026
Frazier Life Sciences Management, L.P.752KUS$10.1MSep 30, 2026
Millennium713KUS$9.61MSep 30, 2026
NEXTBio Capital Management LP684KUS$9.22MSep 30, 2026
AQR Capital Management LLC589KUS$7.93MSep 30, 2026
TD585KUS$7.86MSep 30, 2026
ArrowMark Colorado Holdings LLC583KUS$7.85MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.556KUS$7.49MSep 30, 2026
Royce & Associates LP535KUS$7.21MSep 30, 2026
Ikarian Capital, LLC523KUS$7.04MSep 30, 2026

This page holds 50 of 195 holders. Open Shareholders

Funds

HolderSharesValueAs of
State Street(R) SPDR(R) S&P(R) Biotech ETF3.27MUS$35.4MJun 30, 2026
Vanguard Total Stock Market Index Fund2.92MUS$31.6MJun 30, 2026
iShares Russell 2000 ETF1.95MUS$21.1MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.1.53MUS$16.6MJun 30, 2026
T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund1.26MUS$13.7MJun 30, 2026
T. Rowe Price New Horizons Fund, Inc.1.11MUS$12.1MJun 30, 2026
Eventide Healthcare & Life Sciences Fund951KUS$10.3MJun 30, 2026
Vanguard Extended Market Index Fund943KUS$10.2MJun 30, 2026
Fidelity Small Cap Index Fund818KUS$9.05MJul 31, 2026
Fidelity Growth Company Fund718KUS$6.07MMay 31, 2026
Show 50 holders
HolderSharesValueAs of
Franklin Biotechnology Discovery Fund659KUS$7.3MJul 31, 2026
Vanguard Explorer Fund527KUS$5.83MJul 31, 2026
iShares Russell 2000 Value ETF483KUS$5.23MJun 30, 2026
iShares Biotechnology ETF431KUS$4.66MJun 30, 2026
U.S. Small Cap Portfolio404KUS$4.47MJul 31, 2026
Fidelity Extended Market Index Fund399KUS$3.38MMay 31, 2026
Meridian Contrarian Fund370KUS$4.01MJun 30, 2026
Schwab U.S. Small-Cap ETF366KUS$3.09MMay 31, 2026
Victory Science & Technology Fund358KUS$3.97MJul 31, 2026
Vanguard Russell 2000 Index Fund340KUS$2.87MMay 31, 2026
Dimensional U.S. Small Cap ETF334KUS$3.7MJul 31, 2026
Fidelity Enhanced Small Cap Core ETF299KUS$3.24MJun 30, 2026
U.S. Micro Cap Portfolio298KUS$3.3MJul 31, 2026
T. Rowe Price Small-Mid Cap ETF276KUS$2.98MJun 30, 2026
Victory RS Small Cap Growth Fund261KUS$2.83MJun 30, 2026
iShares Micro-Cap ETF251KUS$2.72MJun 30, 2026
Fidelity Growth Company K6 Fund230KUS$1.95MMay 31, 2026
iShares Russell 2000 Growth ETF215KUS$2.32MJun 30, 2026
Royce Small-Cap Fund207KUS$2.24MJun 30, 2026
Dimensional U.S. Core Equity 2 ETF199KUS$2.2MJul 31, 2026
T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity Fund184KUS$2MJun 30, 2026
Schwab Small-Cap Index Fund181KUS$2MJul 31, 2026
Small Cap Equity Fund162KUS$1.76MJun 30, 2026
Goldman Sachs Small Cap Value Insights Fund156KUS$1.73MJul 31, 2026
Royce Micro-Cap Fund146KUS$1.59MJun 30, 2026
Avantis U.S. Small Cap Equity ETF146KUS$1.24MMay 31, 2026
Fidelity Total Market Index Fund145KUS$1.22MMay 31, 2026
Master Small Cap Index Series140KUS$1.51MJun 30, 2026
T.Rowe Price Small Cap Growth Portfolio135KUS$1.46MJun 30, 2026
North Square Dynamic Small Cap Fund131KUS$1.11MMay 31, 2026
Vanguard Health Care Index Fund130KUS$1.1MMay 31, 2026
Fidelity Series Total Market Index Fund117KUS$991KMay 31, 2026
Goldman Sachs Small Cap Equity Insights Fund116KUS$1.28MJul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF116KUS$1.25MJun 30, 2026
U.S. Core Equity 2 Portfolio112KUS$1.23MJul 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares111KUS$1.23MJul 31, 2026
JPMorgan Small Cap Value Fund109KUS$1.18MJun 30, 2026
T. Rowe Price Health Sciences Portfolio107KUS$1.16MJun 30, 2026
Nuveen Small Cap Blend Index Fund99,143US$1.1MJul 31, 2026
Small Company Growth Portfolio94,280US$1.02MJun 30, 2026

This page holds 50 of 196 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Piscitelli Dominic
Officer: Chief Financial Officer
Sale14,000USD 13.53US$189KOct 20, 2026
Heyman Richard A.
Director
Sale3,500USD 12.91US$45,199Oct 1, 2026
Heyman Richard A.
Director
Sale3,200USD 12.91US$41,325Oct 1, 2026
Piscitelli Dominic
Officer: Chief Financial Officer
Sale13,400USD 13.53US$181KSep 28, 2026
Piscitelli Dominic
Officer: Chief Financial Officer
Sale100USD 13.50US$1,350Sep 24, 2026
Piscitelli Dominic
Officer: Chief Financial Officer
Sale500USD 13.51US$6,755Sep 24, 2026
Piscitelli Dominic
Officer: Chief Financial Officer
Sale77,000USD 13.69US$1.05MAug 26, 2026
Heyman Richard A.
Director
Sale7,000USD 12.02US$84,140Jul 24, 2026
Heyman Richard A.
Director
Sale6,100USD 12.02US$73,322Jul 24, 2026
Heyman Richard A.
Director
Sale300USD 12.00US$3,600Jul 6, 2026

Big stakes

StakeStakeSharesDateFiling
Nextech Crossover I GP S.a. r.l.8.40%7.16MJun 30, 2025Schedule 13G
Viking Global Investors LP5.70%6MSep 30, 2026Schedule 13G
BlackRock, Inc.5.60%5.47MDec 31, 2025Schedule 13G
SR One Capital Management, LLC4.75%4.62MAug 12, 2025Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Carl Gordon
Other companies: ADARx Pharmaceuticals, Inc. (Co-head Global Private Equity at OrbiMed Advisors · Since at least Sep 24, 2026); Electra Therapeutics, Inc. (Director · Since at least Sep 18, 2026); BlossomHill Therapeutics, Inc. (Board Member · Since at least Aug 6, 2026); Scribe Therapeutics Inc. (Director · Since at least Jul 23, 2026); Compass Therapeutics, Inc. (Founding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC · Since at least Jun 17, 2020); Keros Therapeutics, Inc. (Director · Since at least Apr 7, 2020); MBX Biosciences, Inc. (Director · Sep 12, 2024 – Feb 14, 2025 · Past); ArriVent BioPharma, Inc. (Director · Jan 25, 2024 – Jan 30, 2024 · Past); Theseus Pharmaceuticals Inc (Director · Oct 6, 2021 – Feb 14, 2024 · Past); Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Terns Pharmaceuticals, Inc. (Director · Feb 4, 2021 – Jul 15, 2024 · Past); Kinnate Biopharma Inc (Director · Dec 2, 2020 – Apr 3, 2024 · Past); Adicet Bio, Inc. (Director · Sep 15, 2020 – Aug 21, 2024 · Past); SpringWorks Therapeutics Inc (Director · Sep 12, 2019 – Sep 12, 2019 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Turning Point Therapeutics Inc (Director · Apr 16, 2019 – Jun 15, 2020 · Past); Alector, Inc. (Director · Feb 6, 2019 – May 10, 2019 · Past); Armo Biosciences Inc. (Director · Jan 25, 2018 – Jun 22, 2018 · Past); X4 Pharmaceuticals, Inc. (Director · Nov 15, 2017 – Jun 5, 2018 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 27, 2016 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – May 18, 2017 · Past); Acceleron Pharma Inc (Director · Sep 18, 2013 – Sep 18, 2013 · Past); Pacira BioSciences, Inc. (Director · Feb 2, 2011 – Feb 8, 2011 · Past); Amarin Corporation plc (Director · Dec 30, 2010 – Sep 4, 2012 · Past); BioCryst Pharmaceuticals, Inc. (Director · May 17, 2006 – May 17, 2006 · Past)
Director · Apr 23, 2020 – Jun 16, 2021 · Past
Richard Heyman
Other companies: Enliven Therapeutics, Inc. (Director · Since at least Feb 23, 2023); PMV Pharmaceuticals, Inc. (Director · Since at least Sep 24, 2020); RayzeBio, Inc. (Director · Sep 14, 2023 – Feb 26, 2024 · Past); Kineta Inc. (Director · Dec 22, 2020 – Jun 2, 2021 · Past); Metacrine Inc (Director · Sep 15, 2020 – May 18, 2022 · Past); Tango Therapeutics, Inc. (Director · Sep 2, 2020 – Sep 2, 2020 · Past); Gritstone bio, Inc. (Director · Sep 27, 2018 – Jun 17, 2022 · Past)
Chairman · Since at least Apr 23, 2020
Mardi C. Dier
Other companies: Madrigal Pharmaceuticals, Inc. (EVP and CFO · Since at least Mar 11, 2024); Prelude Therapeutics Incorporated (Director · Since at least Sep 24, 2020); Acelyrin, Inc. (CFO and CBO · May 4, 2023 – May 9, 2023 · Past); Ultragenyx Pharmaceutical Inc. (CFO & Executive Vice President · Oct 12, 2020 – Oct 14, 2022 · Past); Adamas Pharmaceuticals Inc (Director · Oct 10, 2017 – Jun 2, 2021 · Past); Portola Pharmaceuticals Inc (EVP and CFO · May 21, 2013 – Jul 2, 2020 · Past)
Board Member · Since at least Apr 23, 2020
Richard H. Scheller
Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Alector, Inc. (Board Member · Since at least Feb 6, 2019); 23Andme Holding Co (Director · Jun 16, 2021 – Aug 26, 2024 · Past); BridgeBio Pharma, Inc. (Director · Jun 27, 2019 – Feb 16, 2023 · Past); Xenon Pharmaceuticals Inc. (Director · Mar 16, 2015 – Sep 16, 2019 · Past); Genentech Inc (EVP-RESEARCH · Jan 13, 2006 – Mar 26, 2009 · Past)
Director · Apr 23, 2020 – May 20, 2021 · Past
Steve L. Hoerter
Other companies: MBX Biosciences, Inc. (Chairman, President and CEO, Director · Since at least Apr 7, 2025); C4 Therapeutics, Inc. (Director · Since at least Nov 19, 2024); Constellation Pharmaceuticals Inc (Director · Sep 4, 2018 – Jul 15, 2021 · Past); Deciphera Pharmaceuticals LLC (President and CEO, Director · May 17, 2018 – Jun 11, 2024 · Past); Agios Pharmaceuticals, Inc. (Chief Commercial Officer · Feb 16, 2016 – Mar 1, 2019 · Past); Clovis Oncology Inc (See Remarks · Nov 15, 2011 – Mar 5, 2015 · Past)
Board Member, Chairman and CEO of MBX Biosciences · Since at least Aug 13, 2021
Lori Kunkel
Other companies: Enliven Therapeutics, Inc. (Director · Since at least Apr 8, 2024); Nurix Therapeutics, Inc. (Director · Jul 23, 2020 – May 19, 2025 · Past); Tocagen Inc (Director · Jun 21, 2018 – Oct 4, 2019 · Past); Curis, Inc. (Director · Jan 22, 2018 – Jan 31, 2022 · Past); Loxo Oncology Inc (Director · Nov 2, 2017 – Feb 15, 2019 · Past)
Director · Since at least Jun 9, 2020
Peter Svennilson
Other companies: RAPT Therapeutics Inc (Director · Jun 18, 2020 – May 28, 2021 · Past); Revolution Medicines, Inc. (Director · Jun 17, 2020 – Apr 26, 2021 · Past); Gritstone bio, Inc. (Director · Jun 19, 2019 – Jun 19, 2019 · Past); NGM Biopharmaceuticals Inc (Director · Apr 3, 2019 – Apr 8, 2020 · Past)
Director · Apr 23, 2020 – Jun 16, 2021 · Past
Angie You
Other companies: Attovia Therapeutics, Inc. (Director · Since at least Aug 4, 2026); RayzeBio, Inc. (Director · Sep 14, 2023 – Feb 26, 2024 · Past); Sierra Oncology Inc (Chief Bus. & Strat. Officer · Jul 15, 2015 – Mar 6, 2018 · Past)
Director · Since at least Nov 9, 2021
Pratik Multani
Other companies: Erasca, Inc. (Director · Since at least Jul 15, 2021); Chimerix Inc (Director · Feb 21, 2020 – Apr 21, 2025 · Past); Fate Therapeutics, Inc. (Chief Medical Officer · Sep 30, 2013 – Jan 5, 2015 · Past)
Chief Medical Officer · Since at least Apr 23, 2020
Jacob Chacko
Other companies: 4D Molecular Therapeutics, Inc. (Director · Since at least Dec 10, 2020)
PRESIDENT AND CEO, Director · Since at least Feb 1, 2021
All 18 people
PersonSeat
Christian V. KuhlenGeneral Counsel and Chief Compliance Officer · Since at least Nov 5, 2026
Dan IazzettiVice President, Head of People · Since at least Nov 5, 2026
Dominic PiscitelliChief Financial Officer · Since at least Jul 20, 2022
Edna Chow ManevalExecutive Vice President, Clinical Development · Since at least Nov 5, 2026
Keith LuiSenior Vice President, Commercial and Medical Affairs · Since at least Feb 18, 2025
Kevin Brodbecknewly established role of Chief Technical Officer · Since at least Nov 13, 2025
Lori FriedmanChief Scientific Officer · Since at least Oct 23, 2026
Matthew PanuwatChief Business Officer · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about ORIC Pharmaceuticals, Inc.